In this newly created role, Dr Menrad will be responsible for developing and executing the Company’s research strategy, including its Targeted Thorium Conjugate platform.Dr Menrad brings more than 20 years of experience in the pharmaceutical and biotech industry, with a strong background in oncology therapeutic development. He joins Algeta from Ablynx NV, where he was CSO.